5 STAR Google REVIEWS
Personalized integrative medical care for weight management, GLP-1 support, peptide therapy, hormone health, regenerative medicine and healthy aging.
Director, Optimal Health Medical, LLC
Dr. Henry C. Sobo, M.D., is the Director of Optimal Health Medical, LLC in Stamford, Connecticut. He completed his Internal Medicine residency at Maimonides Medical Center in Brooklyn in 1985 and has decades of experience caring for patients using conventional and integrative approaches.
Professional Affiliations and Expertise
Dr. Sobo has longstanding experience in physician-guided weight management and was first board-certified by the American Board of Bariatric Medicine in 1990. His practice today includes medical weight management, peptide therapy, hormone health, regenerative medicine, IV therapies and individualized integrative medical care.
Dr Sobo was first Board Certified in Weight Loss Medicine by the American Board of Bariatric Medicine in 1990. He dedicates his time, profession, and expertise to help patients looking to lose weight most effectively and safely. epending on diagnosis, treatment goals and clinical appropriateness, weight-management medications may include semaglutide or tirzepatide. Brand names and FDA-approved indications vary by medication and condition.
GLP-1–based medications can support weight management in appropriate patients by affecting appetite, satiety and metabolic signaling. Some semaglutide and tirzepatide products have FDA-approved indications for chronic weight management in specific patient populations. Medication choice, dosing and monitoring should be individualized by a qualified healthcare professional.
Dr. Sobo evaluates peptide therapy within an individualized medical treatment plan based on a patient’s goals, medical history and clinical appropriateness. Evidence varies significantly among peptide compounds and potential uses; some applications remain investigational and should not be interpreted as established clinical benefits. When appropriate, peptide therapy may be considered alongside other physician-guided approaches such as PRP and broader regenerative care. Explore Peptide Therapy and Learn About PRP Treatments
Evidence review date: September 6, 2026. GLP-1 microdosing has attracted substantial consumer and telehealth interest, but direct clinical-trial evidence remains limited. Medication approvals, prescribing information, safety communications, and clinical evidence
Wegovy HD vs. Zepbound is a more complicated comparison than simply placing two weight-loss percentages side by side. Wegovy HD contains semaglutide and uses a higher 7.2 mg once-weekly dose
Hitting a GLP-1 weight loss plateau can be frustrating. A patient may have been losing weight consistently with semaglutide, tirzepatide, nutrition changes, increased activity, and medical follow-up—then suddenly the scale
